Insider Trading & Ownership of James A. Schoeneck

Location
Menlo Park, CA
Summary
The estimated net worth of James A. Schoeneck is at least $62,158 dollars as of 16 Mar 2026. James A. Schoeneck is the Director of Calidi Biotherapeutics, Inc. and owns shares of Calidi Biotherapeutics, Inc. (CLDI) stock worth about $49.9K. James A. Schoeneck is the Director of FIBROGEN INC and owns shares of KYNTRA BIO, INC. (KYNB) stock worth about $12.3K.
Signature
/s/ Lisa Peraza attorney-in-fact for James A Schoeneck
All Insider Reports
All Insider Reports

Follow Filing Activity

Follow James A. Schoeneck and return when a new Insider Trading filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean.

Sign up to save research and follow filings

Quick Takeaways

  • James A. Schoeneck has 3 issuer positions tracked on this page.
  • Estimated disclosed ownership value: $62,158.
  • Recent insider filing activity is available below.

What Changed

  • Largest disclosed position: Calidi Biotherapeutics, Inc. ($49,862).
  • Past-year value change for that position: .

Why This Matters

  • This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
  • You can cross-check role, issuer, and filing chronology directly against the SEC source.

Source Evidence

Filed on Form 4

Insider ownership context is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Ownership of James A. Schoeneck

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
CLDI, CLDWW Calidi Biotherapeutics, Inc. Director $49,862 21 Aug 2025
KYNB FIBROGEN INC Director $12,296 30 Jun 2025
CNTB Connect Biopharma Holdings Ltd Director 16 Mar 2026

Insider Transactions Reported by James A. Schoeneck:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .